Phaseline

Targets › GGCX

GGCX (Vitamin K-dependent gamma-carboxylase): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 4, 2 Phase 2; Gastroenterology, Genitourinary; next expected readout Dec 2026.

Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant epoxidation of vitamin K hydroquinone to vitamin K epoxide. Couples epoxidation and carboxylation in the same active site. (UniProt, P38435)

Open in Phaseline: the race on GGCX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tanta UniversityVitamin K2 (menaquinone-7)
Vitamin K-dependent carboxylation of bone and vascular proteins; cofactor for gamma-carbox
GGCXPhase 4Upper Gastrointestinal Bleeding (UGIB); Chronic Kidney Diseases; Non Alcoholic Steatohepatitis; Non-alcoholic SteatohepatitisDec 2026

Conditions

Upper Gastrointestinal Bleeding (UGIB) (1) Chronic Kidney Diseases (1) Non Alcoholic Steatohepatitis (1) Non-alcoholic Steatohepatitis (1)

Modalities

small molecule (1)

Companies

Tanta University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.